Firefly Neuroscience, Inc.: Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

Firefly Neuroscience (NASDAQ: AIFF) said TMS center customer clinical assessments using its FDA 510(k)-cleared AI-powered EEG/ERP platform Evoke rose about 291% year over year, nearly four-fold. The company said Evoke combines qEEG and ERP to support clinician assessment of conditions including depression, anxiety, and ADHD, including monitoring before, during, and after TMS.

Original reporting
Published Aug 5, 2026, 12:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 12:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$AIFF
Bullish
medium confidence
Mentioned
$AIFF
Relevance
6/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$AIFFBullishMed
01

Why it matters

The company highlights a sharp YoY increase in TMS center customer clinical assessments, positioning it as evidence of expanding adoption and more individualized TMS treatment monitoring.

02

Market read

AIFF’s disclosed 291% YoY increase in TMS center assessments is a fresh adoption datapoint that can move sentiment, but the absence of financial metrics limits conviction.

03

What to watch

The release lacks absolute scan volumes, number of TMS centers/customers, pricing, and whether the metric is recurring; traders may discount the signal without those details.

Relevance 6/10Novelty 6/10Timing: pre-market/early trading today after-hours? (published 2026-08-05 12:15:00+00:00)

Background

Firefly’s Evoke is an FDA 510(k)-cleared AI-powered EEG/ERP platform used to support diagnostic and treatment monitoring, including in TMS center settings.

Company-level read

Ticker impact

$AIFFBullishMedium confidence
Context

Firefly reports a 291% year-over-year increase in TMS center customer clinical assessments using its FDA-cleared Evoke EEG/ERP platform.

Expected impact

Mild-to-moderate positive bias for AIFF, with follow-through likely dependent on whether the company provides additional revenue, customer count, or retention details in future updates.

Evidence & confidence

This is a concrete growth datapoint (291% YoY) tied to a specific product and use case, but it is not accompanied by financial figures (revenue, bookings, margins) or guidance, limiting magnitude and durability of the impact.

Market effects

Reinforces the narrative that AI-assisted neurodiagnostics are gaining traction in clinical workflows, potentially improving sentiment toward EEG/ERP and digital health tools.

No clear regional read-through beyond US clinical adoption messaging.

Limited direct global impact because the metric is specifically about US TMS center customer assessments.

Counterpoint

A large percentage increase may reflect a low base or changes in reporting/engagement, so it may not translate into proportional revenue growth.

Key entities

  • Firefly Neuroscience, Inc.

    NASDAQ-listed AI neurodiagnostics company reporting growth in TMS center usage of its Evoke platform.

  • Evoke (FDA 510(k)-cleared AI-powered EEG/ERP platform)

    Firefly system used for qEEG and ERP brain activity assessments to support clinical decision-making.

  • Transcranial Magnetic Stimulation (TMS) centers

    Clinical environment where Evoke scans are used before, during, and after care.

Related articles

$AIFFHighAI 8/10

AI Stock Firefly Neuroscience (NASDAQ: AIFF) Soars on First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD

Firefly Neuroscience (NASDAQ: AIFF) stock surged 32.77% after announcing a partnership with NeuroSigma to expand access to the FDA-cleared Monarch eTNS(R) System, a non-drug treatment for pediatric ADHD. The stock traded at $1.58 on high volume. Firefly's Evoke(TM) platform provides AI-powered brain function analytics to clinicians. According to a 2024 study, approximately 7.1 million U.S. children have been diagnosed with ADHD, with nearly one-third receiving no treatment.

$AIFFHigh

Firefly Hikes on Partnering with NeuroSigma

Firefly Neuroscience (AIFF) and NeuroSigma partnered to promote NeuroSigma's Monarch eTNS System, a non-drug ADHD treatment, through Firefly's Evoke platform network. AIFF shares rose 38.9% to $1.65. According to a 2024 study, 7.1 million U.S. children have ADHD, with many seeking non-medication treatments.

$FMedAI 8/10

Ford’s Blue Oval Battery Park begins production in Marshall

Ford Motor Co. has started battery production at its $3B BlueOval Battery Park in Marshall, producing lithium-iron-phosphate (LFP) batteries for the upcoming Ford Fathom EV. The facility can produce 40 cells per minute and aims to compete with global battery producers. Gov. Whitmer highlighted the facility's local impact and technological competitiveness.